• 29
Reading Time: 6 minutes

Insulin is best known as the hormone that lowers blood glucose, but it is also a growth factor. Receptors for insulin are present on keratinocytes, fibroblasts and endothelial cells, the very cells that rebuild skin after injury. That observation has prompted decades of interest in applying insulin directly to wounds, and in the last ten years a growing number of trials and meta-analyses have examined whether topical or locally injected insulin can help diabetic foot ulcers heal. This post reviews what that evidence shows, and where its limits lie.

Why Insulin Might Help a Wound Heal

Diabetic foot ulcers often stall in a prolonged inflammatory phase, with impaired cell migration, poor new blood vessel formation and weak collagen deposition. In a 2020 review of animal and human evidence, Wang and Xu described several ways local insulin appears to counter these problems. In experimental models, topical insulin reduced reactive oxygen species, promoted a shift toward reparative (M2) macrophages and increased the anti-inflammatory cytokine IL-10. It enhanced keratinocyte migration and re-epithelialisation through the PI3K–Akt signalling pathway, increased collagen deposition and fibroblast activity, and stimulated endothelial cell migration and tube formation, with increased VEGF and angiopoietin-1 in diabetic wounds.

These are laboratory and animal findings. They explain why the idea is plausible, but they do not by themselves establish a clinical benefit in people with diabetic foot ulcers.

What the Clinical Studies Show

Individual trials

Most human trials of topical insulin are small, single-centre studies, many conducted in South Asia and the Middle East. A representative example is a 2022 randomised prospective study by Nagaraj and Subbiah in Cureus, which compared locally injected insulin (10 IU per square centimetre of wound, diluted and injected into the wound base) with topical phenytoin and with saline dressings in 60 patients with Wagner grade 1–2 ulcers. Mean time to healing was 20.4 days with insulin, 22.9 days with phenytoin and 26.1 days with saline, and healthy granulation tissue at four weeks was seen in 75% of insulin-treated wounds versus 15% in the saline group. The authors acknowledged that systemic adverse effects were not collected and that the groups were small.

Earlier trials summarised by Wang and Xu reported similar directional results, including faster rates of wound area reduction with insulin than with control treatment, though the insulin dose, formulation (solution, cream, gel or liposomal preparation) and application schedule varied considerably between studies.

Pooled evidence

Several meta-analyses have now combined these studies. Liu and colleagues (Endocrine Journal, 2021) pooled four clinical and nine animal studies and reported shorter healing time and higher healing rates with topical insulin, while noting that the number of clinical studies was small. Ramirez-GarciaLuna and colleagues (Plastic and Reconstructive Surgery, 2023) performed a Bayesian network meta-analysis concluding that local insulin improves wound healing across wound types, and highlighted that safety, particularly hypoglycaemia, had not been systematically analysed. Bhuiyan and colleagues (Wound Repair and Regeneration, 2023) found a faster rate of healing with localised insulin in non-diabetic adults, although with very high statistical heterogeneity (I² = 97%).

The most focused analysis to date is a 2025 systematic review and meta-analysis by Hu and colleagues in the Journal of Tissue Viability, which included 12 randomised trials involving roughly 730 patients with diabetic foot ulcers. Compared with controls, topical insulin was associated with shorter healing time (mean difference about 14 days, based on two trials), smaller wound area, more granulation tissue, greater microvessel density, higher VEGF levels and lower inflammatory markers (IL-1, IL-6 and TNF-α). Fasting plasma glucose did not differ significantly between groups, and the authors concluded that the effect on blood glucose control remains uncertain.

Safety and Important Limitations

Across the clinical studies reviewed by Wang and Xu, investigators generally reported no hypoglycaemia, hypokalaemia, local infection, pain or allergic reactions with topical insulin, and blood glucose levels were usually unchanged. However, these safety observations come from small trials that were not designed to detect uncommon adverse events, and several did not formally collect systemic safety data.

The broader evidence base has notable weaknesses. Many trials are small, unblinded and at risk of bias; insulin doses and formulations are not standardised; outcomes such as complete wound closure, recurrence and amputation are rarely reported; and heterogeneity between studies is often very high. Several pooled outcomes rest on only two or three trials. Importantly, the International Working Group on the Diabetic Foot’s 2023 guideline on interventions to enhance healing (Chen and colleagues) does not list topical insulin among the adjunctive therapies it recommends. The guideline continues to emphasise the foundations of care: offloading, debridement, infection control, revascularisation where needed and metabolic management, with only selected adjuncts considered for hard-to-heal ulcers.

Clinical Summary

Topical and locally injected insulin is a biologically plausible, inexpensive and widely available candidate therapy for diabetic foot ulcers. Laboratory studies show effects on inflammation, re-epithelialisation, collagen formation and angiogenesis, and meta-analyses of small randomised trials suggest faster wound area reduction and shorter healing times without obvious effects on blood glucose. However, the trials are small and heterogeneous, dosing is unstandardised, and robust data on complete healing, amputation and safety are lacking. For these reasons topical insulin remains an investigational approach rather than a guideline-endorsed treatment, and larger, well-designed, multicentre trials are needed before its role in diabetic foot ulcer care can be defined.

References

  • Wang J, Xu J. Effects of topical insulin on wound healing: a review of animal and human evidences. Diabetes, Metabolic Syndrome and Obesity. 2020;13:719–727.
  • Liu H, Wang J, Deng Y, Zou G, Xu J. Effects of topical insulin on wound healing: a meta-analysis of animal and clinical studies. Endocrine Journal. 2021;68(8):969–979.
  • Nagaraj J, Subbiah V. The efficacy of local insulin versus topical phenytoin or normal saline in diabetic foot ulcer management: a prospective comparative study. Cureus. 2022;14(10):e30461.
  • Ramirez-GarciaLuna JL, Rangel-Berridi K, Bergeron A, et al. Local insulin improves wound healing: a systematic review and Bayesian network meta-analysis. Plastic and Reconstructive Surgery. 2023;152(6):1114e–1130e.
  • Bhuiyan ZA, Adebayo O, Ahmed Z, et al. Localised insulin administration for wound healing in non-diabetic adults: a systematic review and meta-analysis of randomised controlled trials. Wound Repair and Regeneration. 2023;31(4):516–527.
  • Hu S, Gong Y, Zhang H, Guo X, Li P. The effect of topical insulin therapy on diabetic foot ulcers: a systematic review and meta-analysis. Journal of Tissue Viability. 2025;34(3):100932.
  • Chen P, Vilorio NC, Dhatariya K, et al. Guidelines on interventions to enhance healing of foot ulcers in people with diabetes (IWGDF 2023 update). Diabetes/Metabolism Research and Reviews. 2024;40(3):e3644.

Comments

comments

Author

PV Mayer

Dr. Perry Mayer is the Medical Director of The Mayer Institute (TMI), a center of excellence in the treatment of the diabetic foot. He received his undergraduate degree from Queen’s University, Kingston and medical degree from the Royal College of Surgeons in Ireland.